Remynd NV reported positive phase IIa trial results for its Alzheimer’s drug REM-127, demonstrating cognitive improvement by restoring neuronal calcium homeostasis and reducing pathological tau levels. In parallel, Avidity Biosciences announced encouraging Phase I/II data for del-zota in Duchenne muscular dystrophy, showing disease progression reversal with sustained treatment. Both represent significant advances in targeting complex diseases with novel therapeutic mechanisms.